These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 30535008)

  • 1. Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study.
    Yanai H; Dotan I
    J Crohns Colitis; 2019 Apr; 13(5):539-540. PubMed ID: 30535008
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study.
    Guidi L; Pugliese D; Panici Tonucci T; Berrino A; Tolusso B; Basile M; Cantoro L; Balestrieri P; Civitelli F; Bertani L; Marzo M; Felice C; Gremese E; Costa F; Viola F; Cicala M; Kohn A; Gasbarrini A; Rapaccini GL; Ruggeri M; Armuzzi A
    J Crohns Colitis; 2018 Aug; 12(9):1079-1088. PubMed ID: 29860436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic drug monitoring is predictive of loss of response after de-escalation of infliximab therapy in patients with inflammatory bowel disease in clinical remission.
    Amiot A; Hulin A; Belhassan M; Andre C; Gagniere C; Le Baleur Y; Farcet JP; Delchier JC; Hüe S
    Clin Res Hepatol Gastroenterol; 2016 Feb; 40(1):90-8. PubMed ID: 26138132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Editorial: infliximab de-escalation in inflammatory bowel disease using a therapeutic drug monitoring strategy-early promise but more data needed.
    Gibson DJ; Ward MG
    Aliment Pharmacol Ther; 2019 Mar; 49(6):816-817. PubMed ID: 30811645
    [No Abstract]   [Full Text] [Related]  

  • 5. Primary and secondary nonresponse to infliximab: mechanisms and countermeasures.
    Wong U; Cross RK
    Expert Opin Drug Metab Toxicol; 2017 Oct; 13(10):1039-1046. PubMed ID: 28876147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical value and cost saving of therapeutic drug monitoring of infliximab in adult patients with inflammatory bowel disease.
    Ganesananthan S; Durai D
    Clin Med (Lond); 2020 Mar; 20(Suppl 2):s23-s24. PubMed ID: 32409349
    [No Abstract]   [Full Text] [Related]  

  • 7. Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease.
    Khanna R; Sattin BD; Afif W; Benchimol EI; Bernard EJ; Bitton A; Bressler B; Fedorak RN; Ghosh S; Greenberg GR; Marshall JK; Panaccione R; Seidman EG; Silverberg MS; Steinhart AH; Sy R; Van Assche G; Walters TD; Sandborn WJ; Feagan BG
    Aliment Pharmacol Ther; 2013 Sep; 38(5):447-59. PubMed ID: 23848220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic Drug Monitoring to Guide Infliximab Dose Adjustment is Associated with Better Endoscopic Outcomes than Clinical Decision Making Alone in Active Inflammatory Bowel Disease.
    Kelly OB; Donnell SO; Stempak JM; Steinhart AH; Silverberg MS
    Inflamm Bowel Dis; 2017 Jul; 23(7):1202-1209. PubMed ID: 28498155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reactive Versus Proactive Therapeutic Drug Monitoring in Inflammatory Bowel Disease Patients Treated With Infliximab: A Self-Fulfilling Prophecy.
    Headlam J; Ford AC; Gracie DJ
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1638. PubMed ID: 28529166
    [No Abstract]   [Full Text] [Related]  

  • 10. Letter: therapeutic drug monitoring and inflammatory bowel disease-a call for an urgent standardization of the results.
    Ribaldone DG; Saracco GM; Astegiano M; Pellicano R
    Aliment Pharmacol Ther; 2018 Feb; 47(3):448-449. PubMed ID: 29314133
    [No Abstract]   [Full Text] [Related]  

  • 11. Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab.
    Papamichael K; Chachu KA; Vajravelu RK; Vaughn BP; Ni J; Osterman MT; Cheifetz AS
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1580-1588.e3. PubMed ID: 28365486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort.
    Gecse KB; Lovász BD; Farkas K; Banai J; Bene L; Gasztonyi B; Golovics PA; Kristóf T; Lakatos L; Csontos ÁA; Juhász M; Nagy F; Palatka K; Papp M; Patai Á; Lakner L; Salamon Á; Szamosi T; Szepes Z; Tóth GT; Vincze Á; Szalay B; Molnár T; Lakatos PL
    J Crohns Colitis; 2016 Feb; 10(2):133-40. PubMed ID: 26661272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proactive and Reactive Therapeutic Drug Monitoring of Biologic Therapies in Inflammatory Bowel Disease Are Complementary, Not Mutually Exclusive.
    Steenholdt C
    Clin Gastroenterol Hepatol; 2018 Apr; 16(4):597-598. PubMed ID: 29555230
    [No Abstract]   [Full Text] [Related]  

  • 14. Therapeutic drug monitoring was helpful in guiding the decision-making process for children receiving infliximab for inflammatory bowel disease.
    Deora V; Kozak J; El-Kalla M; Huynh HQ; El-Matary W
    Acta Paediatr; 2017 Nov; 106(11):1863-1867. PubMed ID: 28779489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infliximab Therapeutic Drug Monitoring Changes Clinical Decisions in a Virtual Biologics Clinic for Inflammatory Bowel Disease.
    Selinger CP; Lenti MV; Clark T; Rafferty H; Gracie D; Ford AC; OʼConnor A; Ahmad T; Hamlin PJ
    Inflamm Bowel Dis; 2017 Dec; 23(12):2083-2088. PubMed ID: 29140939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Utility of Infliximab Therapeutic Drug Monitoring among Patients with Inflammatory Bowel Disease and Concerns for Loss of Response: A Retrospective Analysis of a Real-World Experience.
    Mitchell RA; Shuster C; Shahidi N; Galorport C; DeMarco ML; Rosenfeld G; Enns RA; Bressler B
    Can J Gastroenterol Hepatol; 2016; 2016():5203898. PubMed ID: 27957480
    [No Abstract]   [Full Text] [Related]  

  • 17. Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease: An Answer to Optimized Treatment?
    Hoseyni H; Xu Y; Zhou H
    J Clin Pharmacol; 2018 Jul; 58(7):864-876. PubMed ID: 29462502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
    Vande Casteele N; Ferrante M; Van Assche G; Ballet V; Compernolle G; Van Steen K; Simoens S; Rutgeerts P; Gils A; Vermeire S
    Gastroenterology; 2015 Jun; 148(7):1320-9.e3. PubMed ID: 25724455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays.
    Barclay ML; Karim S; Helms ETJ; Keating PE; Hock B; Stamp LK; Schultz M
    Intern Med J; 2019 Apr; 49(4):513-518. PubMed ID: 30091273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proactive Infliximab Drug Monitoring Is Superior to Conventional Management in Inflammatory Bowel Disease.
    Fernandes SR; Bernardo S; Simões C; Gonçalves AR; Valente A; Baldaia C; Moura Santos P; Correia LA; Tato Marinho R
    Inflamm Bowel Dis; 2020 Jan; 26(2):263-270. PubMed ID: 31247074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.